Deep Vein Thrombosis (DVT) Treatment in Hyderabad

A blood clot that forms in a deep vein of the leg or pelvis is dangerous for a reason that is not obvious from the leg symptoms alone: a fragment of that clot can break free, travel through the bloodstream, and lodge in the lung's arteries as a pulmonary embolism — a potentially fatal event that can occur with little or no warning. This is why any patient presenting with sudden one-leg swelling at Renova Century Hospital is treated as a same-day emergency until DVT is confidently excluded by duplex ultrasound.

The risk of embolism is highest in the first days to weeks after clot formation, before the body has had a chance to organise and stabilise the thrombus against the vein wall. This narrow window is precisely why Dr. Sharma's DVT pathway prioritises rapid duplex confirmation and same-day treatment initiation, rather than the delayed outpatient referral pathway many patients experience elsewhere.

Even when a pulmonary embolism does not occur, an inadequately treated DVT frequently leaves behind post-thrombotic syndrome — permanent scarring of the vein and its valves that causes chronic swelling, pain and, in severe cases, ulceration for years afterward. This long-term consequence is a major reason aggressive early treatment matters even in patients who feel their DVT symptoms are 'mild'.

For decades, warfarin was the only oral option for treating DVT — effective, but notoriously difficult to manage, requiring frequent blood tests (INR monitoring), strict dietary consistency around vitamin K-rich foods, and numerous drug interactions. Today, direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban and dabigatran have largely replaced warfarin for uncomplicated DVT, offering fixed dosing, no routine blood monitoring and a lower risk of major bleeding in most patients.

The typical duration of anticoagulation for a first, clearly provoked DVT (following surgery or a long flight, for example) is 3 months. Unprovoked DVT, recurrent clots, active cancer or a confirmed thrombophilia often require extended or indefinite anticoagulation, a decision individualised at follow-up rather than applied as a blanket rule.

Patients frequently ask whether they can simply stop the medication once the leg swelling improves — this is one of the most important messages Dr. Sharma reinforces at every visit: clinical improvement in the leg does not mean the clot has fully organised or that the risk of recurrence and embolism has passed, and premature discontinuation is one of the most preventable causes of DVT recurrence seen in practice.

Not every DVT can be managed with tablets alone. Large clots affecting the iliac and common femoral veins (iliofemoral DVT) carry a much higher risk of severe, lifelong post-thrombotic syndrome if treated with anticoagulation alone, because the clot burden is simply too large for the body to fully clear on its own. In carefully selected patients — typically those presenting within 10–14 days of symptom onset with extensive, limb-threatening swelling — catheter-directed thrombolysis or mechanical thrombectomy in the cath lab can physically remove or dissolve the clot, restoring the vein's natural channel rather than leaving it scarred.

Catheter-directed thrombolysis involves threading a specialised catheter directly into the clot and infusing a clot-dissolving medication over 24 to 48 hours, with the patient monitored closely in a vascular high-dependency setting. Mechanical thrombectomy, using modern aspiration devices, can achieve a similar result in a single session, often with a lower bleeding risk since less or no thrombolytic drug is required.

Following either procedure, if an underlying iliac vein compression (May-Thurner syndrome) or scarring is identified as the cause of the clot, venous stenting is frequently performed in the same sitting to prevent early re-clotting and preserve the improved outflow long term.

In a small subset of patients — those who cannot safely take anticoagulants due to active bleeding, those who develop a new clot despite adequate anticoagulation, or those undergoing urgent surgery who cannot be anticoagulated at all — a temporary filter can be placed in the inferior vena cava (the large vein returning blood from the legs to the heart) to physically trap any clot fragments before they reach the lungs.

These filters are generally intended as temporary protection and are retrieved once the higher-risk period has passed and anticoagulation can be safely resumed, though in select circumstances a permanent filter is chosen. Regular follow-up is essential to plan timely retrieval, since filters left in place indefinitely carry their own long-term risks of migration or vein perforation.

Pregnancy-related DVT, cancer-associated DVT and paediatric DVT each carry distinct management nuances — different drug choices, different monitoring intervals and different duration of therapy — and are managed individually by Dr. Sharma's team in coordination with the treating obstetrician or oncologist where relevant.